Figure 6.

Therapeutic oral treatment with PXS‐4728A reduces airway fibrosis and remodelling in experimental COPD. Mice were exposed to CS or normal air on 5 days per week for 12 weeks. For the last 6 weeks, mice were treated daily by oral gavage prior to CS‐exposure with PXS‐4728A, rolipram or vehicle. Lungs were perfused, and inflated and airway associated fibrosis and remodelling were assessed by measuring the deposition of collagen around small airways in stained sections. (A) Representative micrographs of sections stained with Masson's Trichrome Blue. (B) Area of fibrosis around the small airways. (C) Hydroxyproline detected in lung lobes. Data represent the means ± SEM from 6–8 mice per group. *P < 0.05; significantly different as indicated; one‐way ANOVA with Tukey's test.